InstaRX review

InstaRX publishes what its NAD⁺ costs, in both routes, on a plan grid you can read before intake. It also names independent provider groups involved in care and shows a LegitScript seal. The headline needs care: the injection's $108 is a first-month price, and the plan then bills $188 a month unless you prepay a longer term. It names no compounding pharmacy, bars returns and exchanges after shipment, and describes state coverage differently on its homepage and NAD⁺ page.

InstaRX is a multi-product compounded-medication telehealth platform with a published address at 15061 Springdale St. Suite 206, Huntington Beach, California. Its anti-aging line is NAD⁺ in two routes — an injection offered from 500 to 1,000 mg and a needle-free nasal spray for daily use at home — alongside compounded semaglutide and tirzepatide for weight loss and sexual-health treatments, all managed from one account. Its current Terms name the operator as InstaRx, Inc. and list two independent provider groups, Dr Telx and MDI Integrations; the current linked terms do not establish the employer of an individual prescriber. It is cash-pay and states that no insurance is needed.

Online intake, review by a licensed U.S. provider, and shipping — a standard asynchronous pipeline, with the useful difference that the prescribing groups are named rather than hidden. The NAD⁺ page sets out the timeline as intake today, provider review and prescription within a day, and free one-to-two-day delivery for new orders, with nursing staff for follow-up. Its expanded shipping policy says recurring orders use ground or two-day service. Naming Dr Telx and MDI Integrations in the Terms is a real disclosure: it identifies organizations involved in care without establishing which one employs the clinician assigned to you. Coverage is stated two ways. The homepage FAQ says the service is available "in all 50 states and the District of Columbia"; the NAD⁺ page says NAD⁺ "is available in most U.S. states", with eligibility confirmed during intake. Treat the narrower wording as the one that applies to NAD⁺ and confirm your state early. The site shows a LegitScript seal linking to LegitScript's checker, which tells you the seal is displayed rather than what LegitScript found. The compounding pharmacy is not named — the site refers only to FDA-registered, state-licensed 503A pharmacies. The linked terms use California law but do not identify which provider group will handle a particular order.

Published for both routes, as a plan grid on the NAD⁺ page. The injection is advertised at "$108 FIRST MONTH", then $188 a month billed monthly; longer terms lower the monthly rate to $158 on a quarterly plan ($474 every three months), $148 on six months ($888) and $145 on twelve months ($1,740 billed upfront). The nasal spray is advertised at $118 for the first month, then $198 a month, or $168, $158 and $155 a month on the same three prepaid terms ($504, $948 and $1,860). So the $108 and $118 figures are first-month promotions, and the standing month-to-month rates are $188 and $198. The site states that every plan includes the provider visit, the prescription and free shipping, with no membership fee. Monthly plans can be canceled at any time; quarterly and longer plans are billed upfront for the whole term. The refund terms are narrow: the shipping and refund page says it cannot accept returns or exchanges once an order has shipped. Before prepaying a long term, ask what happens to the unused months if a provider changes your dose or stops treatment.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. InstaRX states plainly that compounded drugs are not FDA-approved and describes its dispensing pharmacies as FDA-registered, state-licensed 503A facilities with batch testing for potency, sterility, pH and endotoxins, but it does not name them, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. Its NAD⁺ page also calls NAD⁺ "the fountain-of-youth peptide"; NAD⁺ is a coenzyme, not a peptide, and that framing is marketing. On the evidence, both routes on offer here are the ones without data. Injected and intranasal NAD⁺ have no controlled human outcome trials supporting the energy, focus or longevity claims the category is sold on; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly. The NAD⁺ forms with human trial data are the oral precursors NR and NMN, and they reliably raise blood NAD⁺ — a raised biomarker, not a demonstrated clinical outcome. Individual results vary.